Preventive Cancer Vaccine Trial Releases Two-Year Safety Evaluation

Latest news article

10/04/2021

PHOENIX, AZ: BUSINESS WIRE –The Vaccine Against Canine Cancer Study (VACCS) trial (www.vaccs.org) reported its formal two-year evaluation of the safety of a vaccine to prevent cancer in healthy dogs. The largest interventional trial in dogs, it is sponsored by the Open Philanthropy Project, with additional support from Calviri, Inc., a biotech spinout from Arizona State University.

The VACCS trial intends to enroll up to 800 dogs in an equal arm, double-blind study of the vaccine versus mock inoculation. The Data Safety Monitoring Board (DSMB) for the VACCS trial is headed by Dr. Rod Page, director of the Flint Animal Cancer Center at Colorado State University. The DSMB evaluated the clinical records of over 600 dogs in the trial at the two-year mark, 300 of which had received the vaccine with yearly boosters. The DSMB concluded that there were no serious adverse events associated with the vaccination protocol in either arm of the study.

Read in full in our news section

Watch our latest video

About Calviri

Calviri’s mission is to provide affordable products worldwide that will end deaths from cancer by combining a unique, highly immunogenic source of neoantigens with a peptide array platform. On our course to eradicate cancer we will develop new diagnostic and therapeutic products, and then preventative vaccines that will stop cancer from starting.

  • Clinical trials are in progress to demonstrate the feasibility of providing prophylactic vaccines that prevent cancer.
  • Partnerships are formed to collaboratively established the viability of early cancer diagnosis.
  • FAST vaccine trials are being initiated that could dramatically reduce the time and expense of cancer treatments.

Our broad portfolio

Team

STEPHEN ALBERT JOHNSTON

Founding CEO, Chairman BOD

Stephen Albert Johnston is the inventor of the Calviri’s central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics), Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute’s Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.

MARC WOLFF

CEO

Marc Wolff brings more than 23 years of experience in the life sciences industry in various global general management and finance leadership roles. Prior to joining Calviri, Marc Wolff served as Chief Operating Officer and Chief Financial Officer of Aldevron, where he played a key role in scaling the company through exponential growth, enabling Aldevron’s clients to access essential GMP materials for their novel applications in gene and cell therapy. During his tenure, employees grew from 150 to 560 in little over two years, and the company built the world’s largest GMP plasmid DNA and GMP mRNA facility. Prior to Aldevron, Mr. Wolff was instrumental in supporting the growth of a clinical stage specialty pharmaceutical company and oversaw the successful completion of two private equity backed life science company mergers. Additionally, he spent fifteen years with Cardinal Health and Catalent in global general management and finance executive roles.

KATHRYN SYKES, PH.D

VP Research & Product Development

Kathryn Sykes has decades of experience inventing and developing innovative molecular, genetic and biochemical technologies to manipulate the immune system towards better health. She grew the labs at HealthTell and served as V.P. of Research. Previously, she was a professor in the School of Life Sciences at the Biodesign Institute at Arizona State University. At the University of Texas Southwestern Medical School she pursued technologies that became the basis of a Texas biotechnology company, ultimately acquired by Macrogenics. Dr. Sykes received her B.S. in Biology and Economics from Duke University and her Ph.D. in Biochemistry and Genetics from Duke University Medical Center.

DOUGLAS THAMM DVM, PH.D.

Head of Clinical Research

Dr. Thamm is a member of the Developmental Therapeutics Section of the University of Colorado Comprehensive Cancer Center and the Cell and Molecular Biology Graduate Program at Colorado State University. He has authored over 115 peer-reviewed publications and 20 book chapters as well is editor for prominent veterinary journals.His interests include novel targeted therapies for cancer. Thamm received his degrees from the University of Pennsylvania. He completed an Oncology Residency at the University of Wisconsin.

TERRENCE O’NEIL

Director of Production

Terrence O’Neil has over 20 years of experience in multiple industries including Biotechnology, Manufacturing, Retail, and Banking. He is an accomplished leader with an outstanding record of success in project management, strategic planning, program development, organizational management. At HealthTell he served the role of Manager of Operations and provided strong leadership to scale-up operations in this early stage company. He increased his responsibility as Director of Program Management at iCarbonX, Inc. Previously, he held management positions at multiple Fortune 500 companies. Mr. O’Neil received his B.A. in Biochemistry from Arizona State University.

Board of Directors

STEPHEN ALBERT JOHNSTON

Stephen Albert Johnston is the inventor of the Calviri’s central technologies. In addition to Calviri, he has been a founder of Eliance, Inc. (Macrogenics),Synbody Biotechnology and HealthTell, Inc. He is Director of the Arizona State University Biodesign Institute’s Center for Innovations in Medicine and Professor in the School of Life Sciences. He has published almost 200 peer-reviewed papers and holds 45 patents. Prior to his appointment at ASU he was Professor and Director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University. He is a member of the National Academy of Inventors. Dr. Johnston received his B.S. and Ph.D. degrees from the University of Wisconsin.

JACQUE SOKOLOV, M.D.

Dr. Sokolov is chairman and chief executive officer of SSB Solutions, Inc., a US based and diversified healthcare management, development and financial services company. Following his formal training as an academic cardiologist, He started his career as Vice President for Healthcare and Chief Medical Officer for Southern California Edison Corporation. Dr. Sokolov currently serves or has served in multiple board capacities for Public Companies including Hospira, MedCath, and PhyAmerica; Private Companies including Veterans Accountable Care Group, GlobalMed, SMG Holding Company, MyHealthDirect, NeuLife Neurological Services, LLC, IntelaTrak, PCA Holdings and SSB Solutions/HCDG; and Non Profit Organizations including Phoenix Children’s Hospital and numerous others. Dr. Sokolov received his BA and MD Degree from the University of Southern California. He completed his internal medicine residency at the Mayo Graduate School of Medicine and his fellowship in cardiovascular diseases from the University of Texas-Southwestern Medical School.

KATHRYN SYKES, PH.D

Kathryn Sykes has decades of experience inventing and developing innovative molecular, genetic and biochemical technologies to manipulate the immune system towards better health. She grew the labs at HealthTell and served as V.P. of Research. Previously, she was a professor in the School of Life Sciences at the Biodesign Institute at Arizona State University. At the University of Texas Southwestern Medical School she pursued technologies that became the basis of a Texas biotechnology company, ultimately acquired by Macrogenics. Dr. Sykes received her B.S. in Biology and Economics from Duke University and her Ph.D. in Biochemistry and Genetics from Duke University Medical Center.

MICHAEL CHAMBERS

Michael Chambers co-founded Aldevron in 1998, holding the position of President and CEO until this year. He is now Chairman of its Board. Using a technology platform that he co-invented, Aldevron started producing plasmid DNA for biotech researchers in a small lab on the campus of North Dakota State University (NDSU) in Fargo, ND. He and his co-founder built what is today considered the industry’s leading and most respected contract manufacturing organizations in the world. The company utilizes industry-enabling technologies to make recombinant products including nucleic acids, gene editing enzymes, proteins and antibodies. Exemplifying ongoing success, an additional manufacturing plant of 190,000 square-feet building is under construction. In recognition of his significant contributions to the industry, Chambers was named as one of the “100 Most Intriguing Entrepreneurs” by Goldman Sachs in 2018. He received Bachelor of Science degrees in biotechnology, chemistry, and microbiology from NDSU.

MICHAEL McCALLISTER

Michael McCallister has a breadth experience in areas spanning from the medical insurance industry, to financial services, and finally to the animal health care world. One of his many accomplishments as Humana’s CEO for 12 years includes partnering with the CDC to expand on traditional private-sector approaches to population health management. In addition to Humana’s Board, he has also served on the AT&T and Fifth Third Bancorp Boards. He is currently a member of Zoetis, Inc.’s Board of Directors.

Investors

We thank our current investors for their support.

investors-new5

Investors

We thank our current investors for their support.

  • FAST Therapeutic Vaccine
  • Early Detection
  • Responders vs. Non-Responders
  • Antibody-based
  • Highly Sensitive
  • Inexpensive & Simple
  • New Market
  • Shared Neoantigens
  • Preventative Cancer Vaccine